SCHEMBL647136

SCHEMBL647136

C[Si](C)(C)CCN1C(=O)CN(c2ccc(Cc3ccccc3)cc2OCc2ccccc2)S1(=O)=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
HSD17B10 Q99714 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
CYP19A1 P11511 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
LTA4H P09960 1/20 0.34
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32
PTGER1 P34995 2/20 0.32
CYP1A2 P05177 1/20 0.32
PDE4B Q07343 1/20 0.32
BCHE P06276 1/20 0.32
LIPC P11150 1/20 0.32
ACHE P22303 1/20 0.32
LIPE Q05469 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL647168 0.91 CHRNA7 (0.34) CHRNA7ALDH1A1MAPTHSD17B10KDM4C
SCHEMBL646575 0.91 CYP19A1 (0.35) CHRNA7ALDH1A1MAPTHSD17B10KDM4C
SCHEMBL3918925 0.90 CHRNA7 (0.33) CHRNA7ALDH1A1MAPTHSD17B10KDM4C
SCHEMBL648847 0.90 PTGER1 (0.33) CHRNA7ALDH1A1MAPTHSD17B10KDM4C
SCHEMBL649516 0.90 MTNR1A (0.35) CHRNA7ALDH1A1MAPTHSD17B10KDM4C
SCHEMBL646608 0.90 ACHE (0.33) CHRNA7ALDH1A1MAPTHSD17B10KDM4C
SCHEMBL3927311 0.89 CYP19A1 (0.36) CHRNA7ALDH1A1CYP19A1CYP11B1CYP11B2
SCHEMBL3917894 0.89 TRPV3 (0.34) CHRNA7ALDH1A1MAPTHSD17B10KDM4C
SCHEMBL646477 0.89 MAOA (0.36) CHRNA7ALDH1A1MAPTCYP19A1CYP11B1
SCHEMBL647698 0.89 CHRNA7 (0.34) CHRNA7CYP19A1CYP11B1CYP11B2PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963294-B1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) NOVARTIS AG (CH) 2012-10-10 EP disclosed
US-8119666-B2 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) NOVARTIS AG (CH) 2012-02-21 US disclosed
US-20080293776-A1 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1963294-A1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007067613-A1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293776-A1 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) PTPRS, PTPN5, PTPRR CHRNA7 4025/4885ALDH1A1 2398/4885MAPT 3152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.